These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22526844)

  • 21. The beta-glucosidase isozymes and the enzymatic defect in Gaucher disease.
    Patrick AD
    Prog Clin Biol Res; 1982; 95():287-308. PubMed ID: 6812075
    [No Abstract]   [Full Text] [Related]  

  • 22. In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling.
    Kuo CL; Kallemeijn WW; Lelieveld LT; Mirzaian M; Zoutendijk I; Vardi A; Futerman AH; Meijer AH; Spaink HP; Overkleeft HS; Aerts JMFG; Artola M
    FEBS J; 2019 Feb; 286(3):584-600. PubMed ID: 30600575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneity in human acid beta-glucosidase revealed by cellulose-acetate electrophoresis.
    Sa Miranda MC; Aerts JM; Pinto RA; Magalhaes JA; Barranger JA; Tager JM; Schram AW
    Biochim Biophys Acta; 1988 May; 965(2-3):163-8. PubMed ID: 3130106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl.
    Lu J; Chiang J; Iyer RR; Thompson E; Kaneski CR; Xu DS; Yang C; Chen M; Hodes RJ; Lonser RR; Brady RO; Zhuang Z
    Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21665-70. PubMed ID: 21098288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of miRNAs that modulate glucocerebrosidase activity in Gaucher disease cells.
    Siebert M; Westbroek W; Chen YC; Moaven N; Li Y; Velayati A; Saraiva-Pereira ML; Martin SE; Sidransky E
    RNA Biol; 2014; 11(10):1291-300. PubMed ID: 25584808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology.
    Ridley CM; Thur KE; Shanahan J; Thillaiappan NB; Shen A; Uhl K; Walden CM; Rahim AA; Waddington SN; Platt FM; van der Spoel AC
    J Biol Chem; 2013 Sep; 288(36):26052-26066. PubMed ID: 23880767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
    McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
    Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.
    Grabowski GA; Goldblatt J; Dinur T; Kruse J; Svennerholm L; Gatt S; Desnick RJ
    Am J Med Genet; 1985 Jul; 21(3):529-49. PubMed ID: 3927728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In situ radiation-inactivation size of fibroblast membrane-bound acid beta-glucosidase in Gaucher type 1, type 2 and type 3 disease.
    Choy FY; Woo M; Potier M
    Biochim Biophys Acta; 1986 Mar; 870(1):76-81. PubMed ID: 3947649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR/Cas9 Editing for Gaucher Disease Modelling.
    Pavan E; Ormazabal M; Peruzzo P; Vaena E; Rozenfeld P; Dardis A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease.
    van Weely S; Brandsma M; Strijland A; Tager JM; Aerts JM
    Biochim Biophys Acta; 1993 Mar; 1181(1):55-62. PubMed ID: 8457606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacterial β-Glucosidase Reveals the Structural and Functional Basis of Genetic Defects in Human Glucocerebrosidase 2 (GBA2).
    Charoenwattanasatien R; Pengthaisong S; Breen I; Mutoh R; Sansenya S; Hua Y; Tankrathok A; Wu L; Songsiriritthigul C; Tanaka H; Williams SJ; Davies GJ; Kurisu G; Cairns JR
    ACS Chem Biol; 2016 Jul; 11(7):1891-900. PubMed ID: 27115290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of a comprehensive protocol for the identification of Gaucher disease in Brazil.
    Michelin K; Wajner A; de Souza FT; de Mello AS; Burin MG; Pereira ML; Pires RF; Giugliani R; Coelho JC
    Am J Med Genet A; 2005 Jul; 136(1):58-62. PubMed ID: 15937950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble and membranous neutral beta-glucosidases.
    Ben-Yoseph Y; Nadler HL
    Prog Clin Biol Res; 1982; 95():465-80. PubMed ID: 6812082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical study on beta-glucosidase in individuals with Gaucher's disease and normal subjects.
    Michelin K; Wajner A; Goulart Lda S; Fachel AA; Pereira ML; de Mello AS; Souza FT; Pires RF; Giugliani R; Coelho JC
    Clin Chim Acta; 2004 May; 343(1-2):145-53. PubMed ID: 15115687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple forms of beta-glucosidase in Gaucher disease.
    Yaqoob M; Carroll M
    Prog Clin Biol Res; 1982; 95():453-63. PubMed ID: 6812081
    [No Abstract]   [Full Text] [Related]  

  • 38. Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type-1 Gaucher tissues.
    Choy FY
    Am J Med Genet; 1985 Jul; 21(3):519-28. PubMed ID: 4025386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.
    Serra-Vinardell J; Díaz L; Gutiérrez-de Terán H; Sánchez-Ollé G; Bujons J; Michelakakis H; Mavridou I; Aerts JM; Delgado A; Grinberg D; Vilageliu L; Casas J
    Int J Biochem Cell Biol; 2014 Sep; 54():245-54. PubMed ID: 25084554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity.
    Ron I; Horowitz M
    Hum Mol Genet; 2005 Aug; 14(16):2387-98. PubMed ID: 16000318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.